British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

The asset in question is GSK’s 72.5% stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare, famous for the malted ... healthcare nutrition products in March this year.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...